In yesterday’s Wall Street session, Bristol-Myers Squibb Co. (NYSE:BMY) shares traded at $48.90, down -3.82% from the previous session.
27 analysts cover Bristol-Myers Squibb Co. (NYSE:BMY), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $90.00 and a low of $50.00, we find $60.00. Given the previous closing price of $50.84, this indicates a potential upside of 18.02 percent. BMY stock price is now -12.04% away from the 50-day moving average and -22.94% away from the 200-day moving average. The market capitalization of the company currently stands at $99.50B.
The stock has received a hold rating from 16 analysts and a buy rating from 8. Brokers who have rated the stock have averaged $64.05 as their price target over the next twelve months.
With the price target reduced from $68 to $55, Cantor Fitzgerald Downgraded its rating from Overweight to Neutral for Bristol-Myers Squibb Co. (NYSE: BMY).
In other news, Powell Ann, EVP, Chief Human Resources sold 17,986 shares of the company’s stock on Aug 24. The stock was sold for $1,101,642 at an average price of $61.25. Upon completion of the transaction, the EVP, Chief Human Resources now directly owns 27,868 shares in the company, valued at $1.36 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 03, EVP, Chief Research Officer Plenge Robert M sold 732 shares of the business’s stock. A total of $44,754 was realized by selling the stock at an average price of $61.14. This leaves the insider owning 6,584 shares of the company worth $0.32 million. Insiders disposed of 685,218 shares of company stock worth roughly $33.51 million over the past 1 year. A total of 0.07% of the company’s stock is owned by insiders.
On Monday morning Bristol-Myers Squibb Co. (NYSE: BMY) stock kicked off with the opening price of $48.78. During the past 12 months, Bristol-Myers Squibb Co. has had a low of $49.49 and a high of $81.43. As of last week, the company has a debt-to-equity ratio of 1.35, a current ratio of 1.18, and a quick ratio of 1.07. The fifty day moving average price for BMY is $55.59 and a two-hundred day moving average price translates $63.46 for the stock.
The latest earnings results from Bristol-Myers Squibb Co. (NYSE: BMY) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.83, beating analysts’ expectations of $1.61 by 0.22. This compares to $0.75 EPS in the same period last year. The net profit margin was 18.44% and return on equity was 26.87% for BMY. The company reported revenue of $10.97 billion for the quarter, compared to $11.22 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.25 percent. For the current quarter, analysts expect BMY to generate $10.32B in revenue.